Skip to main content
ANIK logo

ANIK · Anika Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track ANIK — free
$13.59 -0.03 (-0.22%) Play latest call Q3 2026 earnings call transcript
Market Cap
$182.44M
Shares
13.40M
Volume · Nov 19 2153 Avg daily vol (3M) 107.13K

Anika Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Anika Therapeutics, Inc. (ANIK), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-06
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Confident tone Manufacturing efficiency and capacity Elective surgery seasonality Hyaluronic acid innovation pipeline
Revenue
$30.59M
▲ 10% YoY
Diluted EPS
$-0.02
Gross margin
61.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-07-29
Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript
Confident tone International OA pain management growth Operational excellence and margin expansion OEM channel and J&J / DePuy Synthes partnership
Revenue
$32.61M
▲ 15.6% YoY
Diluted EPS
$0.24
Gross margin
65.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
Confident tone Integrity regenerative product performance Operational discipline and gross margin Capital allocation and share repurchase
Revenue
$29.61M
▲ 13.2% YoY
Diluted EPS
$-0.37
Gross margin
64.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
Positive tone Commercial channel revenue growth International OA pain portfolio Integrity regenerative platform
Revenue
$30.61M*
▲ 0% YoY
Gross margin
62.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript
Positive tone Hyalofast Regulatory Pathway Cingal NDA Progress Integrity Adoption
Revenue
$27.82M
▼ 5.9% YoY
Diluted EPS
$-0.16
Gross margin
56.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript
Cautious tone Hyalofast Phase III Trial Results Integrity Product Momentum Cingal NDA Progress
Revenue
$28.22M
▼ 8.2% YoY
Diluted EPS
$-0.28
Gross margin
50.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Anika Therapeutics, Inc. (ANIK) Q1 2025 Earnings Call Transcript
Balanced tone Commercial channel growth Integrity implant traction Supply and production issues
Revenue
$26.17M
▼ 9.8% YoY
Diluted EPS
$-0.34
Gross margin
56.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
Anika Therapeutics, Inc. (ANIK) Q4 2024 Earnings Call Transcript
Positive tone Integrity Implant System Growth Hyalofast Regulatory Progress Cingal Development
Revenue
$30.60M*
Gross margin
56.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript
Positive tone Regenerative Solutions pipeline OA Pain Management focus Strategic restructuring and divestitures
Revenue
$29.56M
▼ 28.7% YoY
Diluted EPS
$-2.03
Gross margin
65.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Anika Therapeutics, Inc. (ANIK) Q2 2024 Earnings Call Transcript
Confident tone Regenerative product Integrity launch OA Pain Management franchise (Orthovisc/Monovisc/Cingal) Path to profitability and cost savings
Revenue
$30.72M
▼ 30.6% YoY
Diluted EPS
$0.00
Gross margin
66.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
Positive tone OA Pain Management Cingal U.S. FDA Path Joint Preservation and Restoration
Revenue
$29.02M
▼ 23.5% YoY
Diluted EPS
$-0.31
Gross margin
65.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-13
Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
Confident tone 2024 guidance and MDR / international Integrity Implant System OA Pain Management / Cingal
Revenue
−$2.90M*
Gross margin
-199.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Anika Therapeutics, Inc. (ANIK) Q3 2023 Earnings Call Transcript
Revenue
$41.47M
▲ 3% YoY
Diluted EPS
$-0.45
Gross margin
60.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Anika Therapeutics, Inc. (ANIK) Q2 2023 Earnings Call Transcript
Revenue
$44.30M
▲ 11.7% YoY
Diluted EPS
$-0.19
Gross margin
65.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Anika Therapeutics, Inc. (ANIK) Q1 2023 Earnings Call Transcript
Revenue
$37.92M
▲ 3.4% YoY
Diluted EPS
$-0.71
Gross margin
60.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Anika Therapeutics, Inc. (ANIK) Q4 2022 Earnings Call Transcript
Revenue
−$2.79M*
▼ 107.8% YoY
Gross margin
-135.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Anika Therapeutics, Inc. (ANIK) Q3 2022 Earnings Call Transcript
Revenue
$40.26M
▲ 1.8% YoY
Diluted EPS
$-0.29
▼ 825% YoY
Gross margin
56.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Anika Therapeutics, Inc. (ANIK) Q2 2022 Earnings Call Transcript
Revenue
$39.66M
▲ 4% YoY
Diluted EPS
$-0.20
▼ 144.4% YoY
Gross margin
62.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Anika Therapeutics, Inc. (ANIK) Q1 2022 Earnings Call Transcript
Revenue
$36.69M
▲ 7% YoY
Diluted EPS
$-0.20
▼ 200% YoY
Gross margin
59.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Anika Therapeutics, Inc. (ANIK) Q4 2021 Earnings Call Transcript
Revenue
$35.82M*
▲ 9.6% YoY
Gross margin
50.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Anika Therapeutics, Inc. (ANIK) Q3 2021 Earnings Call Transcript
Revenue
$39.54M
▲ 24.7% YoY
Diluted EPS
$0.04
Gross margin
58.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Anika Therapeutics, Inc. (ANIK) Q2 2021 Earnings Call Transcript
Revenue
$38.15M
▲ 24.3% YoY
Diluted EPS
$0.45
Gross margin
54.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Anika Therapeutics, Inc. (ANIK) Q1 2021 Earnings Call Transcript
Revenue
$34.29M
▼ 3.1% YoY
Diluted EPS
$0.20
▼ 50% YoY
Gross margin
61.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-04
Anika Therapeutics, Inc. (ANIK) Q4 2020 Earnings Call Transcript
Revenue
$32.69M
▲ 9.8% YoY
Diluted EPS
$-1.10
▼ 492.9% YoY
Gross margin
51.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Anika Therapeutics, Inc. (ANIK) Q3 2020 Earnings Call Transcript
Revenue
$31.69M
▲ 6.7% YoY
Diluted EPS
$-0.45
▼ 168.2% YoY
Gross margin
54.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Anika Therapeutics, Inc. (ANIK) Q2 2020 Earnings Call Transcript
Revenue
$30.68M
▲ 0.9% YoY
Diluted EPS
$-0.54
▼ 180.6% YoY
Gross margin
44.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Anika Therapeutics, Inc. (ANIK) Q1 2020 Earnings Call Transcript
Revenue
$35.40M
▲ 43.2% YoY
Diluted EPS
$0.40
▲ 29% YoY
Gross margin
59.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Anika Therapeutics, Inc. (ANIK) Q4 2019 Earnings Call
Revenue
$29.77M
▲ 10.4% YoY
Diluted EPS
$0.28
▼ 48.1% YoY
Gross margin
70.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 898437 CUSIP 035255108 13F (30d) 141 filings 126 filers Visit website Investor relations